Home
Live Updates
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 : comparemela.com
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis...
Related Keywords
Philadelphia ,
Pennsylvania ,
United States ,
Steven Nichtberger ,
William Gramig ,
Anup Marda ,
Cabaletta Bio Inc ,
American College Of Rheumatology Convergence ,
Stern Investor Relations Inc ,
Exchange Commission ,
Drug Administration ,
Nasdaq ,
Investigational New Drug ,
Rheumatic Diseases ,
Chief Executive Officer ,
American College ,
Rheumatology Convergence ,
Cabaletta Bio ,
Private Securities Litigation Reform Act ,
Nature Medicine ,
Orphan Drug Designation ,
Fast Track Designation ,
Investor Relations ,
Markets ,
comparemela.com © 2020. All Rights Reserved.